Double targeted therapy in refractory SpA/PsA. 76 patients, 17 Spanish centres, up to 6 years follow-up. Median 4 prior biologics. Remission achieved in 55.6% during follow-up. 28.6% in remission at final visit. ASDAS improved significantly from 3 months, sustained to 5 https://t.co/g1IPstYYuX